Literature DB >> 30933592

The Affordable Care Act In The Heart Of The Opioid Crisis: Evidence From West Virginia.

Brendan Saloner1, Rachel Landis2, Bradley D Stein3, Colleen L Barry4.   

Abstract

West Virginia is at the epicenter of a national opioid crisis, with a 2016 fatal opioid overdose rate of 43.4 per 100,000 population-more than triple the US average. We used claims data for 2014-16 to examine trends in treatment for opioid use disorder (OUD) among people enrolled in the West Virginia Medicaid expansion program under the Affordable Care Act. Expanding Medicaid could provide services to populations that may previously have had limited access to OUD treatment. We thus sought to understand trends over time in OUD diagnosis and treatment, especially with medications. About 5.5 percent of all enrollees were diagnosed with OUD per year, and the monthly prevalence of OUD diagnoses nearly tripled during this three-year period. The ratio of people filling buprenorphine to the number diagnosed with OUD was around one-third in early 2014, increasing to more than 75 percent by late 2016. Mean annual duration of filled buprenorphine increased from 161 days in 2014 to 185 days in 2016, and most people filling buprenorphine also received counseling and drug testing during the study period. The growing use of medication treatment for OUD in the West Virginia Medicaid expansion population provides an opportunity to reduce overdose deaths.

Entities:  

Keywords:  Affordable Care Act; Buprenorphine; Medicaid expansion; access to care; opioid use disorder

Year:  2019        PMID: 30933592      PMCID: PMC7066526          DOI: 10.1377/hlthaff.2018.05049

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  13 in total

1.  The role of health insurance on treatment for opioid use disorders: Evidence from the Affordable Care Act Medicaid expansion.

Authors:  Angélica Meinhofer; Allison E Witman
Journal:  J Health Econ       Date:  2018-06-30       Impact factor: 3.883

2.  Confronting the stigma of opioid use disorder--and its treatment.

Authors:  Yngvild Olsen; Joshua M Sharfstein
Journal:  JAMA       Date:  2014-04-09       Impact factor: 56.272

3.  Impact of Medicaid Expansion on Medicaid-covered Utilization of Buprenorphine for Opioid Use Disorder Treatment.

Authors:  Hefei Wen; Jason M Hockenberry; Tyrone F Borders; Benjamin G Druss
Journal:  Med Care       Date:  2017-04       Impact factor: 2.983

4.  Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.

Authors:  Marc R Larochelle; Dana Bernson; Thomas Land; Thomas J Stopka; Na Wang; Ziming Xuan; Sarah M Bagley; Jane M Liebschutz; Alexander Y Walley
Journal:  Ann Intern Med       Date:  2018-06-19       Impact factor: 25.391

5.  The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone.

Authors:  Bradley D Stein; Adam J Gordon; Mark Sorbero; Andrew W Dick; James Schuster; Carrie Farmer
Journal:  Drug Alcohol Depend       Date:  2011-11-16       Impact factor: 4.492

Review 6.  Extended-release injectable naltrexone for opioid use disorder: a systematic review.

Authors:  Brantley P Jarvis; August F Holtyn; Shrinidhi Subramaniam; D Andrew Tompkins; Emmanuel A Oga; George E Bigelow; Kenneth Silverman
Journal:  Addiction       Date:  2018-03-24       Impact factor: 6.526

7.  Impact of Medication-Assisted Treatment for Opioid Addiction on Medicaid Expenditures and Health Services Utilization Rates in Vermont.

Authors:  Mary Kate Mohlman; Beth Tanzman; Karl Finison; Melanie Pinette; Craig Jones
Journal:  J Subst Abuse Treat       Date:  2016-05-09

8.  A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees.

Authors:  Bradley D Stein; Andrew W Dick; Mark Sorbero; Adam J Gordon; Rachel M Burns; Douglas L Leslie; Rosalie Liccardo Pacula
Journal:  Subst Abus       Date:  2018-06-22       Impact factor: 3.716

9.  Validation of key behaviourally based mental health diagnoses in administrative data: suicide attempt, alcohol abuse, illicit drug abuse and tobacco use.

Authors:  Hyungjin Myra Kim; Eric G Smith; Claire M Stano; Dara Ganoczy; Kara Zivin; Heather Walters; Marcia Valenstein
Journal:  BMC Health Serv Res       Date:  2012-01-23       Impact factor: 2.655

10.  Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states.

Authors:  Stephen W Patrick; Melinda B Buntin; Peter R Martin; Theresa A Scott; William Dupont; Michael Richards; William O Cooper
Journal:  Subst Abus       Date:  2018-10-09       Impact factor: 3.984

View more
  10 in total

Review 1.  Improving Access to Evidence-Based Medical Treatment for Opioid Use Disorder: Strategies to Address Key Barriers within the Treatment System.

Authors:  Bertha K Madras; N Jia Ahmad; Jenny Wen; Joshua Sharfstein Sharfstein
Journal:  NAM Perspect       Date:  2020-04-27

2.  Steep rise in drug use-associated infective endocarditis in West Virginia: Characteristics and healthcare utilization.

Authors:  Ruchi Bhandari; Talia Alexander; Frank H Annie; Umar Kaleem; Affan Irfan; Sudarshan Balla; R Constance Wiener; Chris Cook; Aravinda Nanjundappa; Mark Bates; Ellen Thompson; Gordon S Smith; Judith Feinberg; Melanie A Fisher
Journal:  PLoS One       Date:  2022-07-15       Impact factor: 3.752

3.  Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.

Authors:  Gerald Cochran; Julie Bruneau; Nicholas Cox; Adam J Gordon
Journal:  Subst Abus       Date:  2020       Impact factor: 3.716

4.  Specialty Substance Use Disorder Treatment Admissions Steadily Increased In The Four Years After Medicaid Expansion.

Authors:  Brendan Saloner; Johanna Catherine Maclean
Journal:  Health Aff (Millwood)       Date:  2020-03       Impact factor: 6.301

Review 5.  Toward a Typology of Office-based Buprenorphine Treatment Laws: Themes From a Review of State Laws.

Authors:  Barbara Andraka-Christou; Adam J Gordon; Kathryn Bouskill; Rosanna Smart; Olivia Randall-Kosich; Matthew Golan; Rachel Totaram; Bradley D Stein
Journal:  J Addict Med       Date:  2022 Mar-Apr 01       Impact factor: 3.702

6.  An application of agent-based modeling to explore the impact of decreasing incarceration rates and increasing drug treatment access on sero-discordant partnerships among people who inject drugs.

Authors:  Sabriya L Linton; Don C Des Jarlais; Joseph T Ornstein; Matt Kasman; Ross Hammond; Behzad Kianian; Justin C Smith; Mary E Wolfe; Zev Ross; Danielle German; Colin Flynn; Henry F Raymond; R Monina Klevens; Emma Spencer; John-Mark Schacht; Teresa Finlayson; Gabriela Paz-Bailey; Cyprian Wejnert; Hannah L F Cooper
Journal:  Int J Drug Policy       Date:  2021-03-31

7.  Quality of Buprenorphine Care for Insured Adults With Opioid Use Disorder.

Authors:  Kelly E Anderson; Brendan Saloner; Julia Eckstein; Christine E Chaisson; Sarah H Scholle; Lauren Niles; Sydney Dy; G Caleb Alexander
Journal:  Med Care       Date:  2021-05-01       Impact factor: 3.178

Review 8.  Opioid use disorder and treatment: challenges and opportunities.

Authors:  Kim A Hoffman; Javier Ponce Terashima; Dennis McCarty
Journal:  BMC Health Serv Res       Date:  2019-11-25       Impact factor: 2.655

9.  Private health insurance coverage of drug use disorder treatment: 2005-2018.

Authors:  Ramin Mojtabai; Christine Mauro; Melanie M Wall; Colleen L Barry; Mark Olfson
Journal:  PLoS One       Date:  2020-10-09       Impact factor: 3.240

10.  Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA's Advocacy Agenda.

Authors:  Sandra A Springer; Joshua A Barocas; Alysse Wurcel; Ank Nijhawan; Kinna Thakarar; Ruth Lynfield; Hermione Hurley; Jessica Snowden; Alice Thornton; Carlos Del Rio
Journal:  J Infect Dis       Date:  2020-09-02       Impact factor: 5.226

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.